NDA 218230 · Glaxosmithkline
Blujepa
Gepotidacin Mesylate · Oral
NovelPriority reviewCDER novel approval, Mar 25, 2025: To treat uncomplicated urinary tract infections
Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Mar 25, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
24
5 Phase 3, 1 recruiting
FAERS reports
33
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 10, 2026.
BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of the following infections caused by susceptible microorganisms: • Uncomplicated urinary tract infections (uUTI) in female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg). ( 1.1 ) • Uncomplicated urogenital gonorrhea in adult and pediatric patients 12 years of age and older weighing at least 45 kilograms who have limited or no alternative treatment options. Approval of this indication is based on limited clinical safety data for this indication. ( 1.2 , 6.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) 1.1 Treatment of Uncomplicated Urinary Tract Infections BLUJEPA is indicated in female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) for the treatment of uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli , Klebsiella pneumoniae , Citrobacter freundii complex, Staphylococcus saprophyticus , and Enterococcus faecalis . 1.2 Treatment of Uncomplicated Urogenital Gonorrhea BLUJEPA is indicated in adult and pediatric patients 12 years of age and older weighing at least 45 kilograms (kg) who have limited or no alternative options for the treatment of uncomplicated urogenital gonorrhea caused by susceptible strains of Neisseria gonorrhoeae. Approval of this indication is based on limited clinical safety data for BLUJEPA [see Adverse Reactions ( 6.1 )]. 1.3 Usage to Reduce...
Mechanism: BLUJEPA is an antibacterial drug [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 11, 2025 Supplement 1 · Efficacy · priority review LabelLetterSummary Review
- Mar 25, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- BLUJEPA · GEPOTIDACIN MESYLATE EQ 750MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gepotidacin" as an intervention, any sponsor and status, largest first.
- Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04187144 · 1,606 participants · Start Apr 23, 2020 · Primary completion Dec 1, 2022
Drug: Gepotidacin; Placebo matching nitrofurantoin and 2 more · For: Urinary Tract Infections
Sites: Birmingham, Alabama; Homewood, Alabama; Huntsville, Alabama · 113 sites in all
- A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04020341 · 1,531 participants · Start Oct 17, 2019 · Primary completion Nov 30, 2022
Drug: Gepotidacin; Placebo matching nitrofurantoin and 2 more · For: Urinary Tract Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 103 sites in all
- A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital GonorrheaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04010539 · 628 participants · Start Oct 21, 2019 · Primary completion Oct 10, 2023
Drug: Gepotidacin; Ceftriaxone and 1 more · For: Gonorrhea
Sites: Los Angeles, California; Palm Springs, California; DeLand, Florida · 51 sites in all
- A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05630833 · 380 participants · Start Jan 11, 2023 · Primary completion Feb 2, 2024
Drug: Gepotidacin; Nitrofurantoin and 1 more · For: Urinary Tract Infections
Sites: Chiba, Japan; Fukuoka, Japan; Gunma, Japan · 27 sites in all
- Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure InfectionsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02045797 · 126 participants · Start Mar 24, 2014 · Primary completion Jun 29, 2015
Drug: GSK2140944 Lyophile; GSK2140944 Capsules · For: Infections, Bacterial
Sites: Phoenix, Arizona; Anaheim, California; Chula Vista, California · 30 sites in all
- A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria GonorrhoeaePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02294682 · 106 participants · Start Apr 15, 2015 · Primary completion Jul 1, 2016
Drug: GSK2140944 · For: Gonorrhea
Sites: Fountain Valley, California; Los Angeles, California; Palm Springs, California · 14 sites in all
- A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06597344 · 97 participants · Start Oct 2, 2024 · Primary completion Mar 10, 2025
Drug: Gepotidacin · For: Urinary Tract Infections
Sites: Modesto, California; Pasadena, California; San Diego, California · 22 sites in all
GlaxoSmithKlineGSK (GSK)
NCT01615796 · 86 participants · Start Jun 4, 2012 · Primary completion Feb 21, 2014
Drug: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined; Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined · For: Infections, Respiratory Tract
Sites: Randwick, Australia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea8
- drug ineffective5
- off label use3
- abdominal pain2
- dizziness2
- dysarthria2
- nausea2
- abdominal pain upper1
- asthenia1
- back pain1
- drug intolerance1
- dysuria1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 31 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.
Ross JDC, Wilson J, Workowski KA, et al. · Lancet 2025 · Multicenter Study, Clinical Trial, Phase III
- Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials.
Wagenlehner F, Perry CR, Hooton TM, et al. · Lancet 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3).
Scangarella-Oman NE, Butler DL, Breton J, et al. · Antimicrob Agents Chemother 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis.
Ibrahim T, Burhan M, Naveed MA, et al. · J Antimicrob Chemother 2026 · Systematic Review, Meta-Analysis
- Pharmacokinetics of Gepotidacin in Renal Impairment.
Hossain M, Tiffany C, Raychaudhuri A, et al. · Clin Pharmacol Drug Dev 2020 · Clinical Trial, Phase I, Comparative Study
- Efficacy and safety of Gepotidacin for urogenital infections: a systematic review and meta-analysis of randomized controlled trials.
Das A, Alam U, Khan AS, et al. · Infection 2026 · Systematic Review, Meta-Analysis
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.